🆙#ESMO26 Presidential Symposium II: #LCSM
🔥Krascendo 1: Efficacy and Safety of Divarasib (Diva) vs Sotorasib (Soto) or Adagrasib (Ada) in Previously Treated Locally Advanced or Metastatic KRAS G12C-Mutated NSCLC
🎙️ @FSkoulidis
🔢LBA5
🎯Significantly Improved PFS (9.8 vs 5.7mo, HR 0.58; n=338) and OS (17.7 vs 12.0mo, HR 0.56, p=0.0005)
🎯ORR 58.4% vs 32.3%
🎯Discontinuation Due to TRAEs 4.8% vs 11.7%
☑️NCT06497556
🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/348
@OncoAlert @Larvol @myESMO @IASLC @KRASKickers
4 浏览 · 0 赞 · 0 转发 · 0 回复
Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.org🆙 #ESMO26 #LCSM Presidential Symposium 🔥Krascendo 1: Efficacy and Safety of Divarasib vs Sotorasib or Adagrasib in Previously Treated Locally Advanced or Metastatic KRAS G12C-Mutated NSCLC 🎙️ @FSkoulidis 🔢LBA5 🎯Met Primary and Key Secondary Endpoints: Divarasib Significantly Improved PFS and OS vs Sotorasib/Adagrasib ☑️NCT06497556 🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/348 @OncoAlert @Larvol @myESMO @IASLC @KRASKickers在 X 查看被引用的帖子
来源：Hidehito HORINOUCHI · x.com